CNS Pharmaceuticals Inc
CNSP
查看详细走势图
6.580USD
-0.100-1.50%
收盘 12/19, 16:00（美东）报价延迟15分钟
3.78M总市值
0.02市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-1.50%
5天
-15.53%
1月
-2.23%
6月
-34.08%
今年开始到现在
-90.89%
1年
-90.03%
查看详细走势图
TradingKey CNS Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值低估，机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
CNS Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
2
位分析师
买入
评级
52.000
目标均价
+621.22%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
CNS Pharmaceuticals Inc亮点
亮点风险
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
CNS Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
CNS Pharmaceuticals Inc简介
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
公司代码CNSP
公司CNS Pharmaceuticals Inc
CEOClimaco (John Michael)
网址https://cnspharma.com/
常见问题
CNS Pharmaceuticals Inc(CNSP)的当前股价是多少？
CNS Pharmaceuticals Inc(CNSP)的当前股价是 6.580。
CNS Pharmaceuticals Inc的股票代码是什么？
CNS Pharmaceuticals Inc的股票代码是CNSP。
CNS Pharmaceuticals Inc股票的52周最高点是多少？
CNS Pharmaceuticals Inc股票的52周最高点是114.000。
CNS Pharmaceuticals Inc股票的52周最低点是多少？
CNS Pharmaceuticals Inc股票的52周最低点是4.930。
CNS Pharmaceuticals Inc的市值是多少？
CNS Pharmaceuticals Inc的市值是3.78M。
CNS Pharmaceuticals Inc的净利润是多少？
CNS Pharmaceuticals Inc的净利润为-14.86M。
现在CNS Pharmaceuticals Inc(CNSP)的股票是买入、持有还是卖出？
根据分析师评级，CNS Pharmaceuticals Inc(CNSP)的总体评级为买入，目标价格为52.000。
CNS Pharmaceuticals Inc(CNSP)股票的每股收益（EPS TTM）是多少
CNS Pharmaceuticals Inc(CNSP)股票的每股收益（EPS TTM）是432.451。
相关品种
